Vanguard Group Inc. lifted its holdings in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 15.7% in the second quarter, according to its most recent filing with the SEC. The firm owned 2,933,251 shares of the company’s stock after acquiring an additional 397,271 shares during the period. Vanguard Group Inc. owned approximately 6.73% of Global Blood Therapeutics worth $80,224,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. BNP Paribas Arbitrage SA lifted its holdings in Global Blood Therapeutics by 694.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after purchasing an additional 3,975 shares during the last quarter. Great West Life Assurance Co. Can bought a new position in Global Blood Therapeutics during the 1st quarter valued at about $129,000. Legal & General Group Plc lifted its holdings in Global Blood Therapeutics by 10.1% during the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after purchasing an additional 440 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Global Blood Therapeutics during the 2nd quarter valued at about $211,000. Finally, SG Americas Securities LLC lifted its holdings in Global Blood Therapeutics by 93.9% during the 2nd quarter. SG Americas Securities LLC now owns 8,288 shares of the company’s stock valued at $227,000 after purchasing an additional 4,014 shares during the last quarter. 86.22% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Vanguard Group Inc. Has $80.22 Million Stake in Global Blood Therapeutics, Inc. (GBT)” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/10/30/vanguard-group-inc-has-80-22-million-stake-in-global-blood-therapeutics-inc-gbt.html.
In other news, Director Charles J. Homcy sold 70,000 shares of the stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the transaction, the director now owns 83,328 shares of the company’s stock, valued at $2,830,652.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jung Choi sold 3,000 shares of the stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $32.65, for a total transaction of $97,950.00. Following the completion of the transaction, the insider now directly owns 138,455 shares of the company’s stock, valued at approximately $4,520,555.75. The disclosure for this sale can be found here. Insiders sold 79,000 shares of company stock valued at $2,655,850 in the last three months. Company insiders own 5.30% of the company’s stock.
Several brokerages recently issued reports on GBT. Zacks Investment Research raised shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a report on Tuesday, October 10th. Oppenheimer Holdings, Inc. set a $53.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 11th. Needham & Company LLC set a $51.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 18th. Morgan Stanley reissued an “overweight” rating and set a $56.00 price target (up from $51.00) on shares of Global Blood Therapeutics in a report on Friday, October 6th. Finally, J P Morgan Chase & Co reissued a “buy” rating on shares of Global Blood Therapeutics in a report on Monday, October 23rd. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $54.08.
Global Blood Therapeutics, Inc. (GBT) opened at 34.35 on Monday. The company’s market capitalization is $1.50 billion. The firm has a 50 day moving average of $30.56 and a 200-day moving average of $29.24. Global Blood Therapeutics, Inc. has a 52 week low of $13.35 and a 52 week high of $41.15.
Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.06. During the same quarter last year, the company earned ($0.58) EPS. On average, analysts forecast that Global Blood Therapeutics, Inc. will post ($2.44) earnings per share for the current year.
Global Blood Therapeutics Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).
What are top analysts saying about Global Blood Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc. and related companies.